Sareum Holdings (SAR) AI Stock Analysis

• Market Cap: £21.40M
• Dividend Yield: N/A
• Average Volume (3M): 619.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.64
• Revenue Growth: N/A
• EPS Growth: 23.76%
• Country: UK
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 138,065,170
• 10 Day Avg. Volume: 1,134,615
• 30 Day Avg. Volume: 619,716
• PEG Ratio: 0.31
• Price to Book (P/B): 8.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): £43.15M

• Rating: 44 Neutral
• Price Target: 14.50 p ▼(-3.33% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is driven mainly by weak financial performance typical of an early-stage, pre-revenue biotech (ongoing losses and cash burn), only partly offset by a debt-free balance sheet and slightly improved cash outflow. Technical indicators also point to a weak trend with depressed momentum, while valuation is constrained by negative earnings and no dividend support.

Positive Factors

Debt-free balance sheet

A lack of reported debt materially reduces fixed obligations and financing risk, giving management flexibility to time partnerships, R&D spend, or equity raises. Over 2–6 months this structural strength improves solvency resilience versus leveraged peers in biotech development cycles.

Narrowing cash outflow trend

A reduction in cash outflow signals better cost control or project prioritisation, which can extend runway and reduce immediate financing needs. If sustained, this trend supports continuation of discovery programs and strengthens negotiating position in partnership talks over months.

Licensing/partnership revenue model

A business model focused on licensing, milestones and collaboration fees decouples value creation from large commercial infrastructure and can produce non-dilutive milestone cash. Structurally this allows value realisation through partnerships even without internal commercialization capacity.

Negative Factors

Pre-revenue with persistent losses

Being pre-revenue with recurring operating losses means the company cannot self-fund R&D or operations; it must rely on external financing or partner milestones. Over months this constrains strategic optionality and raises execution risk if funding or deals are delayed.

Sustained negative cash flow

Negative operating and free cash flow across reporting periods indicate the business consumes capital faster than it generates it. Even with recent narrowing, sustained negative cash flow pressures liquidity and increases the probability of dilutive financing or partnership-driven conditional funding.

Dependence on external funding and volatile equity

Small, volatile equity and asset fluctuations show the balance sheet is shaped by fundraising/events rather than consistent internal cash generation. This structural reliance on external capital raises execution and dilution risk and can lengthen timelines if capital markets or partners retreat.

Sareum Holdings Business Overview & Revenue Model

Company Description

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

How the Company Makes Money

Sareum’s primary way of generating income is through the monetisation of its drug discovery and development assets rather than product sales. This typically includes (1) partnering/licensing arrangements where third parties obtain rights to Sareum-originated compounds or technology in exchange for upfront payments, potential development and regulatory milestone payments, and downstream royalties on any future product sales; and (2) research funding/fees received under collaboration agreements where Sareum contributes discovery work or intellectual property. If the company does not have active commercialised products, recurring revenue is generally limited and results depend on the timing of licensing deals, collaboration income, and any milestone receipts. Specific current revenue figures, the identity/terms of significant active partnerships, and the exact mix of revenue streams are null.

Sareum Holdings Financial Statement Overview

Summary

Pre-revenue with persistent operating and net losses and ongoing negative free cash flow. Positives include no reported debt and a recent narrowing of cash outflow, but the business remains dependent on external funding.

Income Statement

Sareum Holdings remains pre-revenue (revenue is effectively zero in recent annual periods), with persistent operating losses and negative EBITDA/EBIT each year. Net losses have widened versus earlier years, indicating a heavier cost base without offsetting commercial income. While loss-making is common in biotechnology, the lack of visible revenue traction keeps profitability and earnings quality weak.

Balance Sheet

The balance sheet shows no reported debt, which reduces financial risk and provides flexibility. However, equity is relatively small and has been volatile over time, and returns on equity are consistently negative due to ongoing losses. Asset levels also fluctuate meaningfully year to year, underscoring dependence on funding cycles rather than internally generated growth.

Cash Flow

Cash burn remains significant, with operating cash flow and free cash flow negative across all periods. There is some improvement in the most recent year (cash outflow narrowed versus the prior year), but the business is still not self-funding. Free cash flow closely tracks net losses, reinforcing that ongoing operations require external financing until revenues emerge.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-1.00K	-1.00K	-2.00K	-1.09K
EBITDA	-3.38M	-4.54M	-4.01M	-2.57M	-1.70M
Net Income	-4.44M	-3.42M	-3.19M	-2.17M	-1.50M
Balance Sheet
Total Assets	4.23M	2.77M	2.02M	4.79M	3.08M
Cash, Cash Equivalents and Short-Term Investments	3.55M	1.46M	994.00K	4.26M	2.69M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.95M	653.00K	867.00K	455.00K	284.15K
Stockholders Equity	2.28M	2.11M	1.15M	4.33M	2.80M
Cash Flow
Free Cash Flow	-2.55M	-3.92M	-3.27M	-2.13M	-1.57M
Operating Cash Flow	-2.55M	-3.92M	-3.27M	-2.13M	-1.57M
Investing Cash Flow	89.00K	9.00K	-41.00K	-2.00K	-37.86K
Financing Cash Flow	4.55M	4.38M	0.00	3.71M	2.49M

Sareum Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SAR, the sentiment is Neutral. The current price of 15 is below the 20-day moving average (MA) of 15.15, below the 50-day MA of 17.26, and below the 200-day MA of 17.60, indicating a neutral trend. The MACD of -0.54 indicates Negative momentum. The RSI at 48.14 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:SAR.

Sareum Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	56 Neutral	£27.18M	-1.64	-197.54%	―	3.31%	21.91%
APTA	52 Neutral	£22.25M	-3.03	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£29.97M	-1.92	-53.86%	―	―	―
IMM	46 Neutral	£27.20M	-3.00	3817.30%	―	―	―
SAR	44 Neutral	£21.40M	-3.13	-202.14%	―	―	23.76%
FAB	44 Neutral	£15.63M	-9.67	-210.32%	―	-11.43%	23.40%

Sareum Holdings Corporate Events

Sareum Restarts Key Toxicology Study as TYK2 Pipeline and Partnering Drive Half-Year Progress

Sareum Holdings reported half-year results to 31 December 2025, underscoring progress on its pipeline of kinase inhibitors for autoimmune disease, cancer and neuroinflammation, while ending the period with £2.5 million in cash and a reduced pre-tax loss of £1.9 million. The company is advancing its TYK2/JAK1 portfolio with limited resources, positioning itself through targeted R&D and business development to secure future partnerships and non-dilutive funding.

Operationally, Sareum restarted the Phase 2-enabling toxicology programme for lead psoriasis candidate SDC-1801 after confirming prior control-group safety findings were unrelated to the drug, and expects dosing to finish by mid-2026 with a Phase 2-ready package by year-end. Formulation optimisation to enable higher doses and fewer capsules is nearing completion, and the full Phase 1 dataset has been submitted for peer review, reinforcing management’s view of SDC-1801 as a differentiated, once-daily oral therapy in a competitive autoimmune field.

In oncology, translational work on SDC-1802 has been completed, showing strongest responses in niche, high-unmet-need cancers and prompting Sareum to seek a development partner for further progress. For SRA737, the company continues active partnering discussions supported by positive Phase 1/2 data in anogenital cancers, strengthened economics with a 63.5% revenue share, an active U.S. IND for blood cancers, and extended patent protection on the crystal form to at least 2041.

Sareum is also expanding into neuroinflammatory indications via a collaboration with Receptor.AI to design blood-brain barrier-penetrant TYK2/JAK1 inhibitors, with initial compound batches already synthesised and tested in early assays. To accelerate deal-making across its lead assets, Sareum has engaged a specialist U.S.-based business development consultancy, which management says is already beginning to broaden and speed up partnering discussions, potentially altering the company’s funding mix and risk profile over the medium term.

The most recent analyst rating on (GB:SAR) stock is a Sell with a £13.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Sareum to Release Interim Results and Host Live Investor Presentation

Sareum Holdings said it will publish its unaudited interim financial results for the six months to 31 December 2025 on 12 March 2026. The update will give investors a mid-year view on the progress and financial health of the company as it advances its kinase inhibitor pipeline.

Alongside the figures, Sareum will host a live online investor presentation on the same day via the Investor Meet Company platform, open to existing and prospective shareholders. The event, which will be followed by the publication of the presentation on the company’s website, underscores Sareum’s efforts to broaden engagement and transparency with its retail and institutional investor base.

The most recent analyst rating on (GB:SAR) stock is a Hold with a £15.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.

Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings has restarted its Phase 2-enabling toxicology programme for SDC-1801, a selective TYK2/JAK1 inhibitor in development for autoimmune diseases with an initial focus on psoriasis, after appointing a leading global contract research organisation to run the long-term studies. Supported by preliminary pharmacokinetic work and funded from existing cash resources, the toxicology dosing phase is expected to finish by mid-2026, with the full Phase 2-enabling package targeted for completion by year-end, advancing the asset toward Phase 2 trials and reinforcing its potential as a once-daily, best-in-class oral therapy.

The most recent analyst rating on (GB:SAR) stock is a Hold with a £18.50 price target. To see the full list of analyst forecasts on Sareum Holdings stock, see the GB:SAR Stock Forecast page.